6533b858fe1ef96bd12b5ac1
RESEARCH PRODUCT
Usefulness of antimitochondrial antibody 113-1 in diagnosis and classification of salivary gland tumours with oncocytic differentiation
Beatriz Vera-sireraFrancisco Vera-semperesubject
MalePathologymedicine.medical_specialtymedicine.drug_classMonoclonal antibodyPapillary CystadenomamedicineCarcinomaHumansAgedRetrospective StudiesSalivary glandbiologybusiness.industryAntibodies MonoclonalGeneral MedicineMiddle AgedSalivary Gland Neoplasmsmedicine.diseaseImmunohistochemistryMitochondriamedicine.anatomical_structureMonoclonalAntimitochondrial antibodybiology.proteinImmunohistochemistryFemaleAntibodybusinessdescription
Abstract Introduction and objectives Salivary gland tumours usually show great variability both in their morphopathology as well as their clinical behaviour. In the present study, the usefulness of antimitochondrial monoclonal antibody 113-1 in the diagnosis and categorization of salivary tumours was studied. Material and methods A series of 22 benign and malignant salivary tumours and 5 non-tumoral salivary gland specimens were immunohistochemically analysed using an antimitochondrial monoclonal antibody (Ab Mo 113-1), which recognises a non-glycosylated mitochondrial protein of 60 Kd. Results The use of this antibody allowed us to recognize all salivary tumours with oncocytic differentiation. Two salivary tumours (1 papillary cystadenoma and 1 epithelial-myoepithelial carcinoma) (2/22; 10%) were also reclassified as oncocytic tumoral subtypes, in principle unidentified. Conclusion Our study highlights the usefulness of this antibody to facilitate the classification of salivary tumours, an aspect that may sometimes have not only diagnostic implications, but also prognostic.
year | journal | country | edition | language |
---|---|---|---|---|
2010-03-09 | Acta Otorrinolaringologica (English Edition) |